Receive our newsletter – data, insights and analysis delivered to you
July 15, 2009

Pfizer’s New Alzheimer’s Compounds Pass Phase I Testing

The results from Pfizer's two Phase I safety studies for new Alzheimer's disease compounds showed that the treatment was well tolerated, with no clinical or imaging evidence of vasogenic edema. The compounds tested were PF-04360365, a humanised anti-amyloid monoclonal antibody, and dimebo

By cms admin

The results from Pfizer’s two Phase I safety studies for new Alzheimer’s disease compounds showed that the treatment was well tolerated, with no clinical or imaging evidence of vasogenic edema.

The compounds tested were PF-04360365, a humanised anti-amyloid monoclonal antibody, and dimebon combined with donepezil HCl tablets.

A Phase I, single-dose, dose escalation study (0.1 to 10mg/kg) showed that the investigational compound PF-04360365 was well tolerated in all patients. No sign of clinical or imaging evidence of vasogenic edema, and no new microhaemorrhage or encephalitis were reported in the ongoing follow-up period.

Pfizer vice-president and head of medical affairs for the Primary Care Business Steven Romano said that the company has the investigational compound dimebon (latrepirdine) in Phase III testing and two other compounds in Phase II testing.

The data was presented at the Alzheimer’s Association 2009 International Conference on Alzheimer’s Disease (ICAD) in Vienna, Austria.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU